B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
ATEC
AlphatecANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
News tone is operationally positive because of Q2 growth, margin expansion, positive cash flow, and higher EBITDA guidance, but the share-price reaction was weak or conflicted in secondary coverage. Analyst revisions were constructive, while social, options, short-interest, and employee-sentiment data were unavailable; those fields are left at neutral placeholders and should not be interpreted as positive evidence. Medium coverage and incomplete target-count data argue for monitoring rather than an aggressive thesis.
RankAlpha Sentiment Codex - 2026-09-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystPotential post-Q2 profitability reratingHigh impact
ATEC reported Q2 revenue of $214 million, 16.8% adjusted EBITDA margin, positive free cash flow, and raised FY2026 adjusted EBITDA guidance to approximately $140 million from $134 million. A recovery from the weak post-print reaction is possible if investors refocus on operating leverage [#SEC-8K-2026-08-04].
2026-12-03eventQ3 procedure-volume and surgeon-adoption checkpointHigh impact
Surgical revenue grew 17%, case volume grew 20%, and net new surgeon users grew 24% in Q2. Confirmation that these adoption indicators remain durable would support the reaffirmed FY2026 outlook [#SEC-8K-2026-08-04]. The next reporting date is only a secondary estimate, not company-confirmed.
2026-12-03catalystRevenue-per-case and biologics-attachment repairHigh impact
Stored Q2 earnings-call context indicated revenue per case declined approximately 2.7% year over year and biologics attachment remained below prior-year levels. Improvement would strengthen earnings quality; persistence would pressure the thesis [#PR-EARNINGS-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology